[Capsaicin and lidocaine usage in functional disorders of urinary bladder].
Most of the drugs in the treatment of functional disorders of the urinary bladder has a peripheral effect. Their work consists mainly in reducing detrusor contractility of the bladder, or effects on the afferent innervation. Anticholinergics are the first drugs of choice. An alternative pharmacological treatment is to eliminate the overactivity by acting on the bladder afferent innervation, while not inhibiting its contractility. One option is to modulate the pharmacological activity of sensory mechanisms governing the functioning of the bladder via the vanilloid receptor (TRPV1) and ancyrin (TRPA1). Intravesical treatment with capsaicin or lidocaine only partially reduces bladder sensation. Furthermore, clinical use of lidocaine in the treatment of overactive bladder (OAB) is reduced to intravesical supply before capsaicin instillation to reduce the symptoms associated with initial phase of C-fibres sensitization. This paper presents the current state of knowledge regarding the use of capsaicin and lidocaine in functional disorders of the urinary bladder, as well as discusses the impact of these substances on afferent C-fibres and the activity of the urinary bladder. Based on previous studies intravesical capsaicin and lidocaine therapy is one of the alternative treatment options in selected patients with functional disorders of the urinary bladder (in particular OAB) in addition to standard anticholinergics therapy or the newer generation of therapies using botulinum toxin.
Katedra Patofizjologii, Uniwersytet Jagielloński Collegium Medicum, Kraków. kajus13@poczta.onet.pl
Kajetan
K
Juszczak
Piotr J
PJ
Thor
D001905:Botulinum Toxins / Q000008:administration & dosage; D015220:Calcium Channels / Q000187:drug effects* / Q000378:metabolism; D002211:Capsaicin / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D008012:Lidocaine / Q000627:therapeutic use*; D009419:Nerve Tissue Proteins / Q000187:drug effects* / Q000378:metabolism; D000074025:TRPA1 Cation Channel; D050916:TRPV Cation Channels / Q000187:drug effects* / Q000378:metabolism; D050051:Transient Receptor Potential Channels / Q000187:drug effects* / Q000378:metabolism; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000378:metabolism
D015220:Calcium Channels; D018680:Cholinergic Antagonists; D009419:Nerve Tissue Proteins; D000074025:TRPA1 Cation Channel; C473350:TRPA1 protein, human; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human; D050051:Transient Receptor Potential Channels; D008012:Lidocaine; D001905:Botulinum Toxins; D002211:Capsaicin